Work from 2017 started to address this, with a framework currently in place to work towards a day where everyone in Scotland has a home suitable to meet their needs. In 2002, research showed that children and families were the largest growing segment of the homeless population in the United States, and this has presented new challenges to agencies. In the US, the government asked many major cities to come up with a ten-year plan to end homelessness. One of the results of this was a "Housing First" solution. The Housing First program offers homeless people access to housing without having to undergo tests for sobriety and drug usage. The Housing First program seems to benefit homeless people in every aspect except for substance abuse, for which the program offers little accountability. An emerging consensus is that the Housing First program still gives clients a higher chance at retaining their housing once they get it. A few critical voices argue that it misuses resources and does more harm than good; they suggest that it encourages rent-seeking and that there is not yet enough evidence-based research on the effects of this program on the homeless population. Some formerly homeless people, who were finally able to obtain housing and other assets which helped to return to a normal lifestyle, have donated money and volunteer services to the organizations that provided aid to them during their homelessness. Alternatively, some social service entities that help homeless people now employ formerly homeless individuals to assist in the care process.
Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.This drug was developed by Ablynx NV. On 30 August 2018, it was approved in the European Union for the "treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression".It is an anti-von Willebrand factor humanized immunoglobulin. It acts by blocking platelet aggregation to reduce organ injury due to ischemia. Results of the phase II TITAN trial have been reported.In February 2019, caplacizumab-yhdp (Cablivi, Ablynx NV) was approved in the United States for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP). The drug is used in combination with plasma exchange and immunosuppressive therapy. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. References
External links
"Caplacizumab". Drug Information Portal. U.S. National Library of Medicine.